Quizartinib (AC220)
中文名称:奎扎替尼
目录号:S1526 Purity: 99.52%
Quizartinib (AC220)是一种二代FLT3抑制剂,作用于Flt3(ITD/WT),在MV4-11和 RS4;11细胞中IC50分别为1.1 nM/4.2 nM,作用于Flt3比作用于KIT,PDGFRA,PDGFRB,RET,和CSF-1R选择性高10倍。Quizartinib (AC220)可诱导肿瘤细胞的凋亡。Phase 3。
CAS: 950769-58-1
客户使用Selleck的Quizartinib (AC220)发表文献142篇
- Cell, 2024 S0092-8674(24)00908-5
- Mol Cancer, 2023 10.1186/s12943-023-01837-4
- Mol Cancer, 2022 21(1):156
- Blood, 2022 blood.2021015246
- Cancer Discov, 2021 candisc.0738.2020
- Protein Cell, 2021 10.1007/s13238-021-00858-3
- Cancer Cell, 2020 38(6):872-890.e6
- Cancer Discov, 2019 9(6):756-777
- Cancer Cell, 2018 34(2):315-330
- Blood, 2018 25;131(4):426-438
- Blood, 2018 132(1):67-77.
- Nat Med, 2017 23(1):69-78
- Blood, 2017 130(1):48-58
- Blood, 2016 127(23):2890-902
- Cancer Discov, 2014 4(2):200-15
- Blood, 2014 123(18):2826-37
- Blood, 2014 123(5):734-42
- Cell Rep Med, 2024 5(1):101359
- Blood Cancer J, 2024 14(1):207
- Cancers (Basel), 2024 16(21)3719
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101286
- Am J Hematol, 2023 98(7):1029-1042
- Cell Rep, 2023 42(12):113568
- JCI Insight, 2023 8(17)e168445
- Apoptosis, 2023 10.1007/s10495-023-01911-8
- Cell Death Discov, 2023 9(1):44
- Cancer Cell Int, 2023 23(1):302
- Res Sq, 2023 rs.3.rs-2570204
- Nat Commun, 2022 13(1):6226
- Cell Rep Med, 2022 3(1):100492
- Haematologica, 2022 10.3324/haematol.2022.280884
- J Transl Med, 2022 20(1):300
- Eur J Med Chem, 2022 235:114292
- Mol Cancer Ther, 2022 OF1-OF11
- Mol Cancer Ther, 2022 21(7):1125-1135
- Int J Mol Sci, 2022 23(23)14586
- Mol Cancer Res, 2022 20(2):293-304
- Transl Oncol, 2022 18:101354
- J Pers Med, 2022 12(2)258
- Bone Marrow Transplant, 2022 10.1038/s41409-022-01619-4
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Clin Proteomics, 2022 19(1):30
- Biomicrofluidics, 2022 16-4:044110
- Oncol Lett, 2022 23(2):51
- Leuk Res, 2022 124:106983
- Mol Cell, 2021 S1097-2765(21)00507-4
- Autophagy, 2021 1-10
- Blood Cancer J, 2021 11(3):57
- Clin Cancer Res, 2021 10.1158/1078-0432.CCR-20-3458
- Leukemia, 2021 10.1038/s41375-021-01308-z
- Leukemia, 2021 10.1038/s41375-021-01490-0
- Cancer Res, 2021 canres.0955.2021
- Cancer Res, 2021 canres.3761.2020
- Cell Chem Biol, 2021 S2451-9456(21)00475-X
- Front Immunol, 2021 12:699128
- Cell Death Discov, 2021 7(1):121
- Mol Cancer Ther, 2021 20(4):676-690
- Front Cell Dev Biol, 2021 9:662868
- J Cell Mol Med, 2021 25(24):11039-11052
- Cancers (Basel), 2021 13(14)3464
- Cell Signal, 2021 87:110144
- mSphere, 2021 6(1)e00986-20
- Sci Rep, 2021 11(1):22678
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Drug Metab Dispos, 2021 49(1):53-61
- Chem Biol Drug Des, 2021 10.1111/cbdd.13992
- Thorac Cancer, 2021 10.1111/1759-7714.13849
- Oncol Lett, 2021 21(5):397
- Sci Adv, 2021 7(38):eabf9840
- Haematologica, 2020 15 pii: haematol 2019 244020
- Pharmacol Res, 2020 151:104556
- Cell Rep, 2020 33(1):108221
- Mol Cell Proteomics, 2020 10.1074/mcp.RA119.001504
- Eur J Med Chem, 2020 193:112232
- J Cell Mol Med, 2020 24(3):2308-2318
- J Cell Mol Med, 2020 25
- Transl Oncol, 2020 1;13(4):100766
- Sci Rep, 2020 10(1):16187
- Sci Rep, 2020 10(1):1906
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- FEBS Open Bio, 2020 10.1002/2211-5463.12827
- bioRxiv, 2020 10.1158/2159-8290.CD-20-0738
- BioRxiv, 2020 10.1101/2020.05.26.116392
- Sci Transl Med, 2019
- Autophagy, 2019 15(9):1558-1571
- Cell Rep, 2019 26(11):2916-2928.e13
- Cell Rep, 2019 28(9):2331-2344
- Hemasphere, 2019 3(2):e182
- Int J Mol Sci, 2019 20(19)
- Oncotarget, 2019 10(58):6111-6123
- FEBS Lett, 2019 593(16):2162-2176
- Theriogenology, 2019 126:145-152
- Clin Cancer Res, 2018 24(10):2417-2429
- Clin Cancer Res, 2018 24(1):234-247
- Clin Cancer Res, 2018 24(7):1716-1726
- Leukemia, 2018 32(11):2374-2387
- Leukemia, 2018 32(2):313-322
- Haematologica, 2018 haematol.2018.189399
- Cell Death Dis, 2018 9(2):138
- Oncogene, 2018 37(6):787-797
- mBio, 2018 9(2)e00682-18
- Nephrol Dial Transplant, 2018 10.1093/ndt/gfy385
- Oncotarget, 2018 9(76):34240-34258
- Oncotarget, 2018 9(24):16917-16931
- Neoplasia, 2018 20(1):1-11
- Drug Des Devel Ther, 2018 12:1009-1017
- PLoS One, 2018 13(1):e0190682
- PLoS One, 2018 13(5):e0196805
- Exp Hematol, 2018 58:52-58
- J Ophthalmol, 2018 2018:2518568
- Leukemia, 2017 31(11):2336-2346
- Cancer Res, 2017 77(7):1697-1708
- Blood Adv, 2017 1(20):1635-1644
- Oncotarget, 2017 8(32):52026-52044
- Leuk Lymphoma, 2017 10.1080/10428194.2017.1289522
- Cancer Res, 2016 76(5):1214-24
- Cancer Res, 2016 76(6):1528-37
- Oncotarget, 2016 7(31):49786-49799
- Oncotarget, 2016 7(12):13886-901
- Sci Rep, 2016 6:28032
- PLoS One, 2016 11(7):e0158290
- Ann Hematol, 2016 95(5):783-91
- Int J Hematol, 2016 103(1):95-106
- Leukemia, 2015 29(12):2382-9
- Leukemia, 2015 29(12):2390-2
- Leukemia, 2015 29(4):828-38
- Oncotarget, 2015 6(35):38061-78
- Sci Adv, 2015 1(8):e1500221
- Nat Commun, 2014 5:3672
- Clin Cancer Res, 2014 20(8):2092-103
- Leukemia, 2014 28(11):2197-205
- Leukemia, 2014 28(2):293-301
- Proc Natl Acad Sci USA, 2014 10.1073/pnas.1320661111
- Genes Dev, 2014 28(11):1179-90
- Mol Cancer Ther, 2014 13(10):2315-27
- J Biol Chem, 2014 289(45):31053-65
- PLoS One, 2013 8(8): e71266
- PLoS One, 2013 8(9):e74653
- Leuk Res, 2013 37(11):1557-64
- Br J Pharmacol, 2012 166(3):858-76
化学信息&溶解度
分子量 | 560.67 |
分子式 | C29H32N6O4S |
CAS号 | 950769-58-1 |
Smiles | CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 178.35 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 178.35 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 33.2 mg/mL ( 59.21 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:0.5mg/ml
(0.89mM)
操作示例:以 1 mL 工作液为例,取50μL10mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。